Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension
暂无分享,去创建一个
N. Stockbridge | S. Nathan | M. Richter | P. Hassoun | C. Vizza | K. Antoniou | O. Shlobin | H. Olschewski | R. Saggar | S. Abman | S. Wort | P. Vitulo | M. Psotka | H. Lazarus | L. Piccari | S. Nikkho | E. Shen | J. Chung | P. Fernandes